Skip to content

Author

Anza Muhammad

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Dose-response efficacy and safety of the aldosterone synthase inhibitor baxdrostat in resistant hypertension: a systematic review and network meta-analysis.

Baxdrostat 1 mg and 2 mg significantly increased overall adverse events and hyperkalemia, whereas serious adverse events were not significantly increased, and both higher doses significantly increased hyperkalemia risk.

M. Shahzaib, Hafsa Ali, Muhammad Roshaan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.